NASDAQ: ZNTL Zentalis Pharmaceuticals, Inc. 10-Q

Zentalis doses first Phase 3 patient, selects pivotal dose; cash drops $121M to $212M

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ZNTL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.